Laboratory response to paradigm change in hemophilia treatment

Clin Chem Lab Med. 2023 Jun 15;61(12):e248-e250. doi: 10.1515/cclm-2023-0443. Print 2023 Nov 27.
No abstract available

Keywords: FVIII concentrate; FVIII:C CSA; emicizumab.

Publication types

  • Letter

MeSH terms

  • Factor VIII / therapeutic use
  • Hemophilia A* / diagnosis
  • Hemophilia A* / therapy
  • Humans
  • Laboratories
  • Partial Thromboplastin Time

Substances

  • Factor VIII